Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Atorvastatin 40 mg daily for 12 months reduces cardiovascular events in lymphoma patients treated with anthracyclines.
Read Full NewsShroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.
With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported in the study.
Specifically, the alignment relates to a separate, planned clinical trial referred to as ASPIRE.
1.
Improved end-of-life conversations for cancer patients are identified by a new study.
2.
Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024
3.
New drug combination shows good results in patients with HPV-negative head and neck cancer
4.
Outcomes in Resected Melanoma Influenced by Timing of Recurrence
5.
The risk of cancer is decreased by following international health recommendations.
1.
Botulinum Toxins in Oncology: A New Frontier in Chronic Pain Management and Apoptosis Induction
2.
Symptoms and Causes of Phlegmasia Cerulea Dolens: A Comprehensive Guide
3.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
4.
The Pros and Cons of Steroid Therapy for ITP
5.
Colon Cancer Staging: What You Need to Know
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XIII
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
3.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
4.
Navigating the Complexities of Ph Negative ALL - Part XII
5.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge